Excessive nutrients, especially amino acids, impair insulin action on glucose metabolism in skeletal muscle. We tested the hypothesis that the branched-chain amino acid leucine reduces acute insulin action in primary myotubes via a negative feedback mechanism involving ribosomal protein S6 kinase 1 (S6K1). The effect of S6K1 on glucose metabolism was determined by applying RNA interference (siRNA). Leucine (5 mM) reduced glucose uptake and incorporation to glycogen by 13% and 22%, respectively, compared to the scramble siRNA-transfected control at the basal level. Leucine also reduced insulin-stimulated Akt phosphorylation, glucose uptake and glucose incorporation to glycogen (39%, 39% and 37%, respectively), and this reduction was restored after S6K1 silencing. Depletion of S6K1 enhanced basal glucose utilization and protected against the development of impaired insulin action, in response to excessive leucine. In conclusion, S6K1 plays an important role in the regulation of insulin action on glucose metabolism in skeletal muscle.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131472PMC
http://dx.doi.org/10.1007/s00018-009-8818-yDOI Listing

Publication Analysis

Top Keywords

insulin action
20
skeletal muscle
12
glucose metabolism
12
ribosomal protein
8
protein kinase
8
action glucose
8
metabolism skeletal
8
leucine reduced
8
glucose uptake
8
incorporation glycogen
8

Similar Publications

Diabetes mellitus, characterized by high blood glucose due to inadequate insulin action, comprises two main types: type 1, an autoimmune disease, and type 2, marked by insulin resistance. This review provides a comprehensive overview of diabetes management and treatment advancements. Effective diabetes management includes maintaining blood glucose levels within normal ranges and monitoring HbA1c, a marker reflecting average glucose levels over the past few months.

View Article and Find Full Text PDF

Background: In May 2020, the US Food and Drug Administration (FDA) asked 5 pharmaceutical companies to voluntarily recall some formulations of metformin due to contamination. This observational study sought to provide insight changes in hemoglobin A (HbA) levels when veterans switched to alternative antihyperglycemic agents following the recall.

Methods: This study included veterans aged ≥ 18 years with type 2 diabetes who were receiving health care from Veterans Integrated Service Network 6 and had an active metformin sustained-action (SA) prescription as of June 1, 2020.

View Article and Find Full Text PDF

This review focuses on our current understanding of how growth hormone releasing hormone (GHRH): 1) stimulates GH release and synthesis from pituitary growth hormone (GH)-producing cells (somatotropes), 2) drives somatotrope proliferation, 3) is negatively regulated by somatostatin (SST), GH and IGF1, 4) is altered throughout lifespan and in response to metabolic challenges, and 5) analogues can be used clinically to treat conditions of GH excess or deficiency. Although a large body of early work provides an underpinning for our current understanding of GHRH, this review specifically highlights more recent work that was made possible by state-of-the-art analytical tools, receptor-specific agonists and antagonists, high-resolution in vivo and ex vivo imaging and the development of tissue (cell) -specific ablation mouse models, to paint a more detailed picture of the regulation and actions of GHRH.

View Article and Find Full Text PDF

Synergistic effect of canine FGF-21 combined with insulin in the treatment of canine diabetes.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, 150030, China.

Previous studies have shown that FGF-21 can ameliorate hyperglycemia and improve the level of oxidative stress in vivo in diabetic mice. The hypoglycemic effect is safe and lasting, but it takes a longer time to exert its effect. Insulin treatment of canine diabetes takes effect quickly; however, its action time is short, and it is prone to cause hypoglycemia.

View Article and Find Full Text PDF

Sleep-disordered breathing and cardiometabolic and inflammatory markers in children with overweight/obesity: The role of cardiorespiratory fitness.

Pediatr Obes

January 2025

Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.

Objectives: To investigate the association of sleep-disordered breathing (SDB) severity with cardiometabolic and inflammatory markers independently of the adiposity levels; and to explore the role of cardiorespiratory fitness in these associations in children with overweight/obesity.

Methods: A total of 109 children aged 8-11 years with overweight/obesity were included in this cross-sectional study. SDB was assessed using a scale of the reduce version of the Paediatric Sleep Questionnaire.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!